COPD patients report on new Triple-Therapy inhaler in everyday life
NCT ID NCT06368427
Summary
This study observed how patients with moderate to severe COPD felt after starting a standard triple-inhaler medication (BGF MDI) in real Romanian clinics. It tracked changes in their self-reported breathing symptoms and treatment satisfaction over 6 months. The goal was to understand the real-world experience of using this already-approved medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Baia Mare, Romania
-
Research Site
Bucharest, Romania
-
Research Site
Cluj-Napoca, Romania
-
Research Site
Constanța, Romania
-
Research Site
Craiova, Romania
-
Research Site
Deva, Romania
-
Research Site
Dorohoi, Romania
-
Research Site
Hunedoara, Romania
-
Research Site
Iași, Romania
-
Research Site
Luduş, Romania
-
Research Site
Medgidia, Romania
-
Research Site
Oradea, Romania
-
Research Site
Sighișoara, Romania
-
Research Site
Suceava, Romania
-
Research Site
Târgu Mureş, Romania
-
Research Site
Timișoara, Romania
Conditions
Explore the condition pages connected to this study.